2011 does more than represent multiple years of double digit growth. It validates difficult decisions in the past… and it speaks to the credibility and viability of our company’s strategies today that will direct BDI Pharma successfully into the future.
Columbia, SC (PRWEB) January 25, 2012
BDI Pharma, Inc. (BDI), the nation’s fastest growing national distributor of biotech therapies, announced that sales revenues for the twelve months of fiscal year 2011 represented an increase of more than twenty-nine percent (29%) compared with the same period during calendar year 2010. Units of Product Distributed year to year rose thirty-five percent (35%) during 2011 compared to 2010 substantiating BDI Pharma’s continued successful expansion of its product and service portfolio.
The Specialty Biopharmaceutical class of products, specifically in the clinical area of Oncology, grew by nearly twenty percent (20%) as a whole (branded and generic oncologics) from 2010 to 2011 primarily due to an expanding customer base and a broadening portfolio of product offerings from an increasing number of manufacturing partners. Also notable from 2011 was continued growth within the Protein Biotherapeutics classes, specific to Albumin (24% increase), Hemophilia (36% increase) and Immunology (29% increase). BDI Pharma’s SecuriVAX program recorded a successful sales year as well, distributing one hundred percent (100%) of product purchased for the 2011-2012 influenza season.
“We pride ourselves on being a company that plans for the long-term,” stated Edward Stiefel, Jr. Co-President of BDI Pharma. “2011 does more than represent multiple years of double digit growth. It validates difficult decisions made in the past – decisions that have brought us to this point - and it speaks to the credibility and viability of our company’s strategies today that will direct BDI Pharma successfully into the future.”
About BDI Pharma, Inc.
Since 1995, BDI Pharma has defined its customer-centric approach to serving the nation's healthcare community through innovative supply solutions, unparalleled customer service, extensive product knowledge, 24/7 emergency availability and urgent-need delivery. An open-access resource for reference material, educational literature, market data and online ordering, bdipharma.com (ivig.com) has become an industry-renowned point of reference. Proprietary programs for specialty veterinarians -- 4legpharma.com; product consignment -- consignadvantage.com; flu pre-booking and general vaccine ordering -- securivax.com; and purchasing/reward programs -- qoreprogram.com and securigam.com round out a family of solutions tailored to the needs of the healthcare community at large.
BDI Pharma’s portfolio includes branded and generic specialty biopharmaceuticals, chemotherapy products, vaccines, albumin, IVIG, coagulation factors, high-titer or “hyper” immune globulins, and other specialty injectables. BDI Pharma is recognized as an “ADR,” or Authorized Distributor of Record, for all of the manufacturers it represents.